<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02822196</url>
  </required_header>
  <id_info>
    <org_study_id>HSC-MS-16-0467</org_study_id>
    <nct_id>NCT02822196</nct_id>
  </id_info>
  <brief_title>Serratus Anterior Muscle Plane Block vsThoracic Paravertebral Block For Unilateral Mastectomies</brief_title>
  <official_title>Effectiveness of Serratus Anterior Muscle Plane Block With Thoracic Paravertebral Block For Unilateral Mastectomies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Health Science Center, Houston</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Memorial Hermann Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The University of Texas Health Science Center, Houston</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      HYPOTHESIS

      Serratus Anterior Muscle Plane Block (SPB) is as effective as thoracic paravertebral block
      (PVB) for acute pain control after unilateral mastectomies.

      SPECIFIC AIMS

      Primary aim: To evaluate the efficacy of SPB block vs thoracic PVB for acute pain control in
      patients undergoing unilateral mastectomy

      Secondary aim To compare the onset and duration of block and dermatomes blocked in both
      groups To compare the need of post-operative rescue analgesia in both groups. To compare the
      development of chronic incisional pain in both groups Functional outcome with respect to
      daily activities.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      RESEARCH STRATEGY

        1. Background

           Breast cancer is a potentially deadly disease affecting one in eight women. [1] Majority
           of them undergo mastectomies along with different modalities of treatment like
           chemotherapy, radiotherapy and hormonal treatments.

           Since mastectomy is the main and most commonly preferred treatment for breast cancer
           surgery, it raises the focus on the most frequently studied complication that is
           persistent pain following surgery [8, 9] The incidence of pain syndrome six months
           post-breast cancer surgical treatment was 52.9%.[7] A multivariate analysis of the
           presence of chronic pain in breast cancer survivors revealed risk factors including more
           invasive surgery, radiation therapy after surgery, and clinically meaningful acute
           postoperative pain. Each risk factor independently predicted more intense chronic pain
           at three months after surgery. [8] A 20% prevalence rate of the Post Mastectomy Pain
           syndrome was found. Women experiencing the syndrome reported chronic, stable pain of
           long duration that began shortly after surgery. [10] The syndrome is important to
           recognize because of how debilitating the pain can be. Studies have indicated that post
           mastectomy pain interferes with activities of daily living like driving, taking care of
           the children, leisure time, and sex, all of which result in poor quality of life. It was
           also noted that in women who survived treatment of breast cancer, chronic pain often
           caused mood changes, difficulty at work, and reduction of physical activities. This was
           especially noted in those women whose pain spreads to other areas of the body. [14]

           There are various anesthetic techniques available for management of mastectomies. The
           effectiveness of each technique is widely studied regarding pain control, requirement of
           rescue analgesia, side effects, post-operative hospital stay and development of
           persistent pain following breast cancer surgical treatment. Belzarena SD et al compared
           the effectiveness of thoracic epidural block and general anesthesia for oncologic
           mastectomy. Patients were divided in two groups in which they either received GA or
           thoracic epidural anesthesia as primary anesthetic. [10] The results showed that the
           quality of postoperative analgesia was better in the epidural group, which also
           presented with lower consumption of analgesics. The length hospitalization in this group
           was also lower. They concluded that an epidural block had some advantages when compared
           with general anesthesia and can be considered an anesthesia option in oncologic
           mastectomies with axillary lymph node dissection.

           Newer regional anesthesia techniques have been developed to improve pain control and
           patient satisfaction. These includes epidural blocks (thoracic and cervical), single
           injection thoracic PVB and intercostal nerve blocks. PVB during breast cancer surgery
           have been reported to decrease acute pain and opioid consumption immediately following
           surgery in multiple randomized clinical trials [4, 5, 6] and were superior over epidural
           blocks due to lower complication rate. A thoracic PVB is a well-established anesthetic
           technique and has been proven to be safe for mastectomies.

           The most recent advancement in anesthetic techniques for mastectomies is the SPB. The
           SPB is a novel technique first described by Fajardo et al in 2012 [2]. A single
           injection blocks many dermatomes at once. This technique could be an effective
           alternative to PVB or thoracic epidurals, because it is considered more feasible, safe
           than thoracic epidurals and results in a lower complication rate. But there are very few
           long term randomized studies to prove the efficacy of SPB.

           R. Blanco et al studied this novel ultrasound-guided regional anesthetic technique to
           provide analgesia following surgery on the thoracic wall in four volunteers. All
           volunteers reported an effective block that provided long-lasting paresthesia (750-840
           min). There were no side-effects noted in this initial descriptive study. They have
           suggested to confirm these preliminary results in a large clinical trial.[12] Currently
           only a single major clinical trial comparing the effectiveness of SPB and PVB for Breast
           Cancer Resections is being conducted by Ghada M N Bashandy, National Cancer Institute,
           Egypt. [13]

        2. Protocol/Experimental Design/Flowchart/Primary and Secondary End Points

           Criteria

           Ages Eligible for Study: 18 Years to 80 Years Genders Eligible for Study: Female No. of
           subjects in each group: 50. (Total = 100)

           Informed consent for the procedure will be taken. Patients will be educated on the use
           of the visual analogue scale (VAS) to evaluate their pain level and a printed copy of
           the VAS scoring will be provided to take home. After the completion of preoperative
           assessment by the OR nurse, the patients will be randomized to either SPB group or PVB
           group. The block will be performed pre operatively. To reduce patient anxiety and
           improve comfort, midazolam 0.02mg/kg IV will be given except in patients &gt; 70 years of
           age. Standard ASA monitors were applied including pulse oximetry, noninvasive blood
           pressure, and electrocardiogram.

           Procedure: Serratus Anterior Muscle Plane block (SPB)

           The US probe will be placed in the mid-axillary line at the level of the 5th intercostal
           space. The latissimus dorsi (superficial and posterior), teres major (superior) and
           serratus muscles (deep and inferior) will be identified. Using in-plane approach, the
           block needle (22 G, 50 mm) will be inserted until the tip is visualized between the
           serratus anterior muscle and the intercostal muscles. As an extra reference point
           thoracodorsal artery will be used which aids in the identification of the plane
           superficial to the serratus muscle. After negative aspiration of blood, local anesthetic
           (20 ml of 0.25 % bupivacaine) will be injected and visualized in real-time. [11]

           Procedure: Paravertebral Block (PVB)

           Patients will be placed in the sitting position, leaning forward. After skin
           disinfection using chlorhexidine solution, target spinous processes of T1- T5 will be
           identified and at parasagittal plan at 2.5 cm, skin wheel will be raised using 1%
           lidocaine. A 20-gauge, bevel needle will be advanced until the transverse process is
           located. The depth from skin to transverse process will be marked/identified by needle
           marking. The needle will be withdrawn 1-2 cm and angled down (walked off the transverse
           process). The needle will be re-advanced 1cm past the initial marking. After negative
           aspiration, 4-5 ml of 0.25% bupivacaine will be slowly injected. The same procedure will
           be repeated at each level from T2 to T6 ensuring total dose of bupivacaine does not
           exceed the maximum dose recommended. [13]

           After the block is performed, all subjects will receive induction of general anesthesia
           with fentanyl 1-2 mcg/kg, propofol 1-2 mg/kg and suxamethonium 1 mg/kg. After induction
           the trachea will be intubated with 7.0 mm ID endotracheal tube. For analgesia all
           patients will receive 1 gm of intravenous acetaminophen. Anesthesia will be maintained
           with sevoflurane with oxygen and air. To minimize PONV, every patient will receive
           ondansetron 4mg at the end of the surgery. Fentanyl 25 mcg boluses will be used as
           rescue analgesia intra operatively. When extubation criteria have been met the trachea
           will be extubated and the patient will be taken to PACU.

           PACU phase I For VAS &gt;6, 0.5 mg intravenous hydromorphone every 10 min up to 2 mg as a
           rescue analgesia For VAS &lt;/=6, patient will be given tramadol 100 mg.

           PACU phase II Prior to discharge all patients will receive tramadol 50mg if they have
           not required pain medication in phase I.

           At discharge, all patients will be prescribed Norco (7.5/325) every 4 hours prn for
           VAS&gt;4.

           Reinforcement of previous education on VAS scoring will be done as part of discharge
           instructions by the discharge nurse.

           The following parameters will be recorded in each group.

             -  Duration of block analgesia - time to peak of pain/return of sensation after
                surgery will be recorded

             -  Dermatomal distribution of sensory loss obtained after block tested with ice.

             -  Assessment of static and dynamic VAS scores at 0 (on arrival to PACU), 6, 12, 24
                and 48 hours, 3 months and 6 months after surgery and additional set of questions
                to assess neuropathic pain. ( painDETECT)

             -  Time for 1st rescue analgesia

             -  Total dose of rescue analgesia received during the first 24 and 48 hrs

        3. Sample size and statistical analysis

      Statistical analysis plan StatistiCall will create the randomization list by using the
      software ClinStat (from St. George's Hospital Medical School, Version dated 08.05.96). The
      treatment will be named 1 for SPB Block, 2 for PVB block for both parts of the study in the
      list. Block randomization in X blocks of X patients will be used.

      Since there is no valid data comparing the 2 blocks, we are unable to construct a realistic
      power analysis as the hypothesis of difference between the 2 procedures are potentially
      minimal and not yet statistically proven. Therefore, this initial investigation in 100
      subjects is clinically and logistically feasible and analysis will provide statistical
      guidance to any necessary additional studies.

      The investigators will be responsible for analyzing the study data, and the analysts will be
      blinded to patients' group assignment during the execution of the study. For the purpose of
      the final analysis, the official clinical database will not be unblinded until
      medical/scientific review has been completed and the investigators have been assured that the
      data are complete.

      Before performing any analysis, the distribution of all variables will be examined for
      appropriateness of distribution assumptions. Descriptive statistics will be summarized for
      all variables including demographics, duration of analgesia, VAS scores during rest and after
      surgery, time for 1st rescue analgesia, total dose of rescue analgesia received in 24 hrs and
      side effects. Mean Â± SD will be reported for continuous variables and frequency (percentage)
      will be reported for discrete variables. Analysis of variance or Kruskal-Wallis test as
      appropriate will be used to analyze and compare the primary endpoint VAS among two groups as
      well as the secondary endpoints. Chi-square test or extended Fisher's exact test as
      appropriate will be used for the comparison of the incidence of chronic pain as well as other
      side effects. All analyses will be performed using SAS 9.3 (Cary, NC) and a p-value less than
      0.05 will be considered as statistically significant.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>July 2016</start_date>
  <completion_date type="Anticipated">March 2017</completion_date>
  <primary_completion_date type="Anticipated">January 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of SPB block vs thoracic PVB</measure>
    <time_frame>6 months</time_frame>
    <description>Efficacy of SPB block vs thoracic PVB block as described by reduce post operative pain score and reduce requirement for Narcotics.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Onset and duration of block</measure>
    <time_frame>6 months</time_frame>
    <description>Onset and duration of block as described by the time when block performed to the time of onset of block and Dermatomal distribution of sensory loss (tested with ice)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-operative rescue analgesia</measure>
    <time_frame>up to 24 hours</time_frame>
    <description>Time for 1st rescue analgesia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of chronic incisional pain</measure>
    <time_frame>24 and 48 hours</time_frame>
    <description>Total dose of rescue analgesia received during the first 24 and 48 hrs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain related assessment scores as described in the Pain Detect Questionnaire</measure>
    <time_frame>6 months</time_frame>
    <description>Pain related assessment scores as described in the Pain Detect Questionnaire</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Mastectomy</condition>
  <condition>Regional Anesthesia</condition>
  <condition>Post Operative Pain</condition>
  <arm_group>
    <arm_group_label>Serratus Anterior Muscle Plane Block</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The US probe will be placed in the mid-axillary line at the level of the 5th intercostal space. The latissimus dorsi (superficial and posterior), teres major (superior) and serratus muscles (deep and inferior) will be identified. Using in-plane approach, the block needle (22 G, 50 mm) will be inserted until the tip is visualized between the serratus anterior muscle and the intercostal muscles. As an extra reference point thoracodorsal artery will be used which aids in the identification of the plane superficial to the serratus muscle. After negative aspiration of blood, local anesthetic (20 ml of 0.25 % bupivacaine) will be injected and visualized in real-time.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Thoracic Paravertebral Block</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will be placed in the sitting position, leaning forward. After skin disinfection using chlorhexidine solution, target spinous processes of T1- T5 will be identified and at parasagittal plan at 2.5 cm, skin wheel will be raised using 1% lidocaine. A 20-gauge, bevel needle will be advanced until the transverse process is located. The depth from skin to transverse process will be marked/identified by needle marking. The needle will be withdrawn 1-2 cm and angled down (walked off the transverse process). The needle will be re-advanced 1cm past the initial marking. After negative aspiration, 4-5 ml of 0.25% bupivacaine will be slowly injected. The same procedure will be repeated at each level from T2 to T6 ensuring total dose of bupivacaine does not exceed the maximum dose recommended.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lidocaine</intervention_name>
    <description>Local Anesthesia using 1% Lidocaine</description>
    <arm_group_label>Thoracic Paravertebral Block</arm_group_label>
    <other_name>1% Lidocaine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine</intervention_name>
    <description>Local Anesthesia using 0.25% Bupivacaine</description>
    <arm_group_label>Serratus Anterior Muscle Plane Block</arm_group_label>
    <arm_group_label>Thoracic Paravertebral Block</arm_group_label>
    <other_name>0.25% Bupivacaine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Simple or radical unilateral mastectomy with or without axillary lymph node
             dissection.

          -  American Society of Anesthesia (ASA) I, II and III

        Exclusion Criteria:

          -  Morbid obesity (body mass index &gt; 40 kg/m2);

          -  Renal insufficiency (creatinine &gt; 2.0 mg/DL),

          -  Current chronic analgesic therapy (daily use &gt; 4 weeks),

          -  History of opioid dependence, pregnancy.

          -  Allergy to local anesthetic

          -  Rash/infection at the area of injection

          -  Coagulation disorder

          -  Patients on anticoagulation
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sara Guzman-Reyes, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Texas Health Science Center, Houston</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sara Guzman-Reyes, MD</last_name>
    <phone>713-500-6200</phone>
    <email>Sara.Guzman-Reyes@uth.tmc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tariq A Syed, MS</last_name>
    <phone>713-500-6304</phone>
    <email>Tariq.A.Syed@uth.tmc.edu</email>
  </overall_contact_backup>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 24, 2016</study_first_submitted>
  <study_first_submitted_qc>July 1, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 4, 2016</study_first_posted>
  <last_update_submitted>July 1, 2016</last_update_submitted>
  <last_update_submitted_qc>July 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 4, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of Texas Health Science Center, Houston</investigator_affiliation>
    <investigator_full_name>Sara R Guzman-Reyes</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupivacaine</mesh_term>
    <mesh_term>Lidocaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

